<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05018533</url>
  </required_header>
  <id_info>
    <org_study_id>TAKC-02-001</org_study_id>
    <nct_id>NCT05018533</nct_id>
  </id_info>
  <brief_title>The Safety and Pharmacokinetics Study of TAKC-02 Inhalation Solution in Healthy Adult Males.</brief_title>
  <official_title>The Safety and Pharmacokinetics Study of TAKC-02 Inhalation Solution in Healthy Adult Males.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>TAK-Circulator Co.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>TAK-Circulator Co.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      MEX3B is an RNA-binding protein that is conserved in many animal species and has wide range&#xD;
      of biological function. The MEX3B protein is deeply involved in the expression of various&#xD;
      cytokines associated with the onset and exacerbation of several diseases such as inflammatory&#xD;
      diseases, metabolic diseases, and malignant tumors. TAKC-02 is a nucleic acid medicine,&#xD;
      antisense oligonucleotide, inhibits the MEX3B synthesis expected to have potential as new&#xD;
      medication.&#xD;
&#xD;
      This plans to evaluate the safety profile of the inhalation solution in order to develop&#xD;
      TAKC-02 for severe asthma.&#xD;
&#xD;
      The study is a double-blind, randomized, placebo-controlled Phase I study. The primary&#xD;
      objective of the study is to assess the safety and tolerability of single and multiple&#xD;
      inhaled doses of TAKC-02 in healthy male subjects. The study is a Single Ascending Dose (Step&#xD;
      1) followed by a Multiple Comparative Dose (Step 2).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This initial Phase I study will be conducted in normal healthy male volunteers to obtain an&#xD;
      unconfounded understanding of the safety, tolerability and pharmacokinetics of TAKC-02&#xD;
      inhalation solution. TAKC-02 is being developed as a medication for uncontrolled severe&#xD;
      asthma. The first-in-human, randomized, double-blind trial will evaluate single ascending&#xD;
      doses (SAD) and subsequently multiple ascending doses (MAD) of TAKC-02 and placebo.&#xD;
&#xD;
      Step 1 (SAD) :&#xD;
&#xD;
      There will be 5 cohort of 6 (Cohort 1, 2, 3) or 8 (Cohort 4, 5) subjects each. Subjects in&#xD;
      each cohort are randomized in a 2:1 ratio (Cohort 1, 2, 3) and 3:1 ratio to receive a single&#xD;
      dose of the study drugs, TAKC-02 or Placebo. The SAD study will evaluate the safety and&#xD;
      tolerability of a single dose of TAKC-02 and determine the starting and maximum doses for&#xD;
      Step 2. Pharmacokinetics will be also analyzed. One cohort (cohort 4.5) maybe added depending&#xD;
      on the incidence of adverse effect in the lower dosing group.&#xD;
&#xD;
      Step 2 There will be 2 cohort f 8 subjects each. Subjects in both cohorts are randomized in a&#xD;
      3:1 ratio to receive multiple doses of the study drugs, TAKC-02 or Placebo. The safety and&#xD;
      tolerability of repeated administration of TAKC-02 for 2 weeks will be evaluated, and the&#xD;
      maximum dose of this drug in the next phase will be estimated. Pharmacokinetics will be also&#xD;
      analyzed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">August 17, 2021</start_date>
  <completion_date type="Anticipated">March 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Not applicable to a drug allotment and a dispensing staff</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in the rate of adverse events</measure>
    <time_frame>Up to 7 days after dose</time_frame>
    <description>assessed by the change in number of adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUC from time zero to the time of the last quantifiable concentration (AUC0-t last)</measure>
    <time_frame>Up to 48 hours after last dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax</measure>
    <time_frame>Up to 48 hours after last dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax</measure>
    <time_frame>Up to 48 hours after last dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T1/2</measure>
    <time_frame>Up to 48 hours after last dose</time_frame>
  </secondary_outcome>
  <number_of_arms>16</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Healthy Volunteer</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAKC-02 0.15mg Single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (to Cohort 1)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAKC-02 0.5mg Single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (to Cohort 2)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAKC-02 1.5mg Single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (to Cohort 3)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAKC-02 5mg Single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (to Cohort 4)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4.5 *optional</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAKC-02 10mg Single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (to Cohort 4.5) *optional</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAKC-02 15mg Single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (to Cohort 5)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAKC-02 Multiple dose (low)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (to Cohort 6)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 7</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAKC-02 Multiple dose (high)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (to Cohort 7)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TAKC-02</intervention_name>
    <description>Inhalation Solution</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_label>Cohort 4.5 *optional</arm_group_label>
    <arm_group_label>Cohort 5</arm_group_label>
    <arm_group_label>Cohort 6</arm_group_label>
    <arm_group_label>Cohort 7</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Inhalation Solution</description>
    <arm_group_label>Placebo (to Cohort 1)</arm_group_label>
    <arm_group_label>Placebo (to Cohort 2)</arm_group_label>
    <arm_group_label>Placebo (to Cohort 3)</arm_group_label>
    <arm_group_label>Placebo (to Cohort 4)</arm_group_label>
    <arm_group_label>Placebo (to Cohort 4.5) *optional</arm_group_label>
    <arm_group_label>Placebo (to Cohort 5)</arm_group_label>
    <arm_group_label>Placebo (to Cohort 6)</arm_group_label>
    <arm_group_label>Placebo (to Cohort 7)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Both Step 1 and Step 2 are for healthy adult males who meet all of the following&#xD;
             conditions.&#xD;
&#xD;
               1. Subjects are normal healthy men&#xD;
&#xD;
               2. Aged between 20 and 40 at the time of consent&#xD;
&#xD;
               3. Subjects who have obtained the voluntary consent of the person in writing&#xD;
&#xD;
               4. Subjects with BMI of 18.5 or more and less than 25.0 kg / m2&#xD;
&#xD;
               5. Subjects who can be hospitalized during the cohort transition safety assessment&#xD;
                  period&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Both Step 1 and Step 2 do not apply to those who meet any of the following conditions.&#xD;
&#xD;
               1. Subjects with clinically problematic complications or medical history&#xD;
&#xD;
               2. Subjects with a history of drug allergies&#xD;
&#xD;
               3. Smokers (those who have smoked within 1 year)&#xD;
&#xD;
               4. Subjects with hypersensitivity disease (excluding asymptomatic pollinosis)&#xD;
&#xD;
               5. Those who may affect the absorption, distribution, metabolism and excretion of&#xD;
                  drugs&#xD;
&#xD;
               6. Subjects have been prescribed a drug intended for treatment within 4 weeks before&#xD;
                  administration of the study drug, or those who need administration during the&#xD;
                  period of participation in the study&#xD;
&#xD;
               7. Subjects have used over-the-counter drugs within 4 weeks before administration of&#xD;
                  the study drug, or those who need to use it during the period of participation in&#xD;
                  the study&#xD;
&#xD;
               8. Subjects ingested alcoholic beverages or caffeine-containing beverages within 24&#xD;
                  hours before administration of the study drug&#xD;
&#xD;
               9. Subjects with reduced lung function (FEV1.0% &lt;70%)&#xD;
&#xD;
              10. Subjects with alcoholism or drug addiction&#xD;
&#xD;
              11. Subjects have a positive reaction in the substance abuse test&#xD;
&#xD;
              12. Subjects tested positive for HBsAg, hepatitis C virus (HCV) antibody, HIV antigen&#xD;
                  / antibody, syphilis serum reaction or severe acute respiratory syndrome&#xD;
                  (SARS)-CoV-2 nucleic acid amplification&#xD;
&#xD;
              13. Subjects collected 400 mL or more of whole blood within 16 weeks before&#xD;
                  administration of the study drug or 200 mL or more of blood within 4 weeks, or&#xD;
                  those who collected component blood (plasma component and platelet component)&#xD;
                  within 2 weeks before administration of the study drug, or subjects whose annual&#xD;
                  total blood collection volume exceeds 1200 mL, including the planned blood&#xD;
                  collection volume for clinical trials&#xD;
&#xD;
              14. Subjects have been treated with TAKC-02 in the past&#xD;
&#xD;
              15. Subjects participated in another clinical trial and were administered anther test&#xD;
                  drug within 16 weeks before the administration of the study drug, or those who&#xD;
                  participated in another clinical trial at the same time as this clinical trial.&#xD;
&#xD;
              16. Subjects have been vaccinated against new coronavirus, influenza, etc. within 4&#xD;
                  weeks before the administration of the study drug, or who are scheduled to be&#xD;
                  vaccinated during the period of participation in the study.&#xD;
&#xD;
              17. Subjects are not willing to adhere to proper contraception using effective&#xD;
                  contraception for 3 weeks after the last dose of the study drug from the date of&#xD;
                  admission of study site.&#xD;
&#xD;
              18. Subjects are judged inappropriate to participate in the clinical trial by the&#xD;
                  investigator or the co-investigator.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>TAK-Circulator Clinical Study Team</last_name>
    <phone>+81-3-3830-0875</phone>
    <email>clinical_trial@tak-circ.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>TAKC-02 Study Site</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 17, 2021</study_first_submitted>
  <study_first_submitted_qc>August 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 24, 2021</study_first_posted>
  <last_update_submitted>August 23, 2021</last_update_submitted>
  <last_update_submitted_qc>August 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>antisense oligonucleotides</keyword>
  <keyword>anti asthmatic agents</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Aspiration</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

